Trial Profile
Double-Blind, Placebo-Controlled Dose-Escalation Phase I Study With Recombinant Human Soluble Angiotensin Converting Enzyme 2 (rhACE2) APN01 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alunacedase alfa (Primary)
- Indications Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction
- Focus Adverse reactions
- 01 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2009 New trial record